Disclosure/Enablement Flashcards
Ariad Pharma v Eli Lily, 598 F3d 1336 (Fed Cir 2010)
For written description requirement, step 3- Controlling legal standard “possession as shown in the disclosure”
The Court:
1. Reconfirmed the existence of the written description standard (which had been challenged in the preceding decade)
2. Affirmed the standard applied to all claims;
3. The test must be met on an objective standard based on the “four corners” of the patent;
4. For a genus (class) claim, the requirement may be met by a representative number of species or structural features common to all the members of the genus.
Liquid Dynamics v Vaughan Co, 449 F 3d 1209, 1224 (Fed Cir 2006)
In re Donohue Case
The requirement of enablement is satisfied where the disclosure enables the PSA to make and use the full scope of the claimed invention without undue experimentation.
O’Reilly v Morse, 56 US 62, 114 (1853)
An inventor can only claim what he has invented and described.
Spectra-Physics v Coherent, 827 F 2d 1524, 1533 (Fed Cir 1987)
Date of assessment is the date of filing of the application.
Warner-Lambert v Teva Pharma, 418 4 F3d 1326,1337 (Fed Cir 2005)
Genetech v Novo Nordisk, 108 F 3d 1361, 1366 (Fed Cir 2007)
Two reasons for Enablement in Patent Application:
- The teaching function of the patent, to know what is covered by the patent and what isn’t.
- The invention is sufficiently concrete to warrant a patent (Patent is not general)
- Liebel-Flarsheim v Medrad, 481 F3d 1371, 1382 (Fed Cir 2007)
- EMI Group NA v Cypress Semiconductors, 268 F 3d 1342, 1350 (Fed Cir 2001)
Mosaicking in US-
1. It is permissible to combine prior art for novelty only where there is incorporation by reference.
- This requires a single reference to “expressly or inherently disclose each and every limitation (feature) in the claim.”
Knapp v Morss, 150 US 221, 228 (1893)
Rule- that which infringes later, anticipates earlier:
This means that where a single element is missing from the reference (prior art), the claim is novel.
Rasmusson v SmithKline Beecham, 413 F3d 1318, 1325-6 (Fed Cir 2006)
Enablement for patent application - how to make invention
Enablement for novelty- how to use it
! in theory different but often there is an overlap between the two in practice.
Schering Corp v Geneva Pharmam, 339 F3d 1373, 1377 (Fed Cir 2003)
Inherency in US-similar to EPO
Prior art anticipates if the feature is present inherently/implicitly n the document.
Egbert v Lippmann, 104 US 333 (1881)
The use must be a public use. Public use means “use of the invention by a person other than the inventor who is under no limitation, restriction or obligation of secrecy to the inventor”.
Baxter Int v COBE Lab, 88 F 3d 1054, 1058 (Fed Cir 1996)
Public use, third parties and inventor.
New Railhead Mft v Vermer Mft, 298 F3d 1290 (Fed Cir 2002)
Public land=public use
Metallizing Eng’ing v Kenyon Bearing, 153 F 2d 516, 518 (2d Cir 1946)
Where the inventor uses a process and sells a product based on that process before the filing date they are bared from patenting the process.
UK=process is secret and u keep selling, it’s not public use and u can patent.
If u sell after grace period
City of Elizabeth v American Nicholson Pavement, 97 US 126 (1877)
Experimental use is not a public use
Graham v John Deere, 383 US 1, 6 (1966)
Constitutional link to patent system.
Patent system promotes science and useful arts. If its obvious, not patentable.
Four limb test:
1. Determine scope and content of the prior art;
2. Compare differences between the prior art and the claims at issue;
3. Determine the level of ordinary skill in the art;
4. Determine whether the claims as a whole would have been obvious to the PSA at the time of the invention.
Used to be any flash of genius type approach. (did they deserve patent?)
An objective test now.
